In Compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015, we would like to inform you that the Board of Directors of our Company at their meeting held on 10th January, 2023, approved the Scheme of Amalgamation ('Scheme') under Section 230 to Section 232 and other relevant provisions of the Companies Act, 2013 for amalgamation between MedPlus Health Services Limited ('Transferee Company') and MHS Pharmaceuticals Private Limited ('Transferor Company'), subject to requisite approvals. The Transferor Company is the wholly owned subsidiary of the Transferee Company. We enclose information as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, is annexed. The company pursuant to regulation 37(6) of SEBI(LODR) Regulation 2015, intimate to stock exchange regarding filing of draft scheme of amalgamation to NCLT. (As Per BSE Announcement dated on 08.08.2023) Intimation of NCLT Order approving the scheme of amalgamation u/s 230-232 and other applicable provisions of Companies Act, 2013 and rules made thereunder of MHS Pharmaceuticals Private Limited with MedPlus Health Services Limited under Regulation 30 of SEBI( Listing Obligations and Disclosure) Requirements Regulations, 2015 (As Per BSE Announcement dated on 17.08.2024)